Published in:

21-04-2025 | Anthracycline | REVIEW

Cardio-Oncology and Breast Cancer Therapies

Authors: Rohit Singh, Krina Patel, Haze Xu, Aderonke Adeniyi, Jenica N. Upshaw, Peter Van Buren, Peter A. Kaufman, Kim Dittus, Kara K. Landry

Published in: Current Treatment Options in Oncology | Issue 5/2025

Opinion Statement

Assessing cardiac risk prior to initiating breast cancer treatment, monitoring cardiac function during treatment, and implementing appropriate follow-up strategies are essential components of managing cardiotoxicity in breast cancer patients. A comprehensive cardiovascular evaluation should be conducted before treatment, including a detailed medical history, physical examination, and baseline cardiac imaging. Risk stratification tools can aid in determining the individual patient's risk profile. Close monitoring of cardiac function, including regular assessment of left ventricular ejection fraction (LVEF) and monitoring for signs and symptoms of cardiac dysfunction, is crucial during treatment. Prompt action should be taken if an adverse cardiovascular event is detected, including considering discontinuing or modifying the treatment regimen. Appropriate follow-up care is essential to monitor for long-term cardiac effects and optimize cardiovascular health in breast cancer survivors. Regular cardiovascular assessments, lifestyle modifications, and collaboration between healthcare professionals are important in managing cardiotoxicity effectively.

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation. Accessed June 18, 2024. https://www.ahajournals.org/doi/https://doi.org/10.1161/CIR.0000000000001063

Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. https://doi.org/10.1093/eurheartj/ehac244.CrossRefPubMed

Cardinale D, Colombo A, Bacchiani G, et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation. 2015;131(22):1981–8. https://doi.org/10.1161/CIRCULATIONAHA.114.013777.CrossRefPubMed

Michel L, Mincu RI, Mahabadi AA, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22(2):350–61. https://doi.org/10.1002/ejhf.1631.CrossRefPubMed

Romann SW, Giannitsis E, Frey N, Lehmann LH. Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications. Curr Heart Fail Rep. 2024;21(6):505–14. https://doi.org/10.1007/s11897-024-00681-x.CrossRefPubMedPubMedCentral

Cardio-oncology — A marriage of cardiology & oncology - Mayo Clinic. Accessed January 11, 2025. https://www.mayoclinic.org/medical-professionals/cancer/news/cardio-oncology-a-marriage-of-cardiology-oncology/mac-20491245

Padegimas A, Clasen S, Ky B. Cardioprotective Strategies to Prevent Breast Cancer Therapy-Induced Cardiotoxicity. Trends Cardiovasc Med. 2020;30(1):22–8. https://doi.org/10.1016/j.tcm.2019.01.006.CrossRefPubMed

Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018;71(20):2281–90. https://doi.org/10.1016/j.jacc.2018.02.049.CrossRefPubMed

Wihandono A, Azhar Y, Abdurahman M, Hidayat S. The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients. Asian Pac J Cancer Prev. 2021;22(9):2847–53. https://doi.org/10.31557/APJCP.2021.22.9.2847.CrossRefPubMedPubMedCentral

10.

Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–80. https://doi.org/10.1093/eurheartj/ehw022.CrossRefPubMedPubMedCentral

11.

Hundley WG, D’Agostino R, Crotts T, et al. Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment. NEJM Evidence. 2022;1(9). https://doi.org/10.1056/EVIDoa2200097

12.

Neilan TG, Quinaglia T, Onoue T, et al. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA. 2023;330(6):528–36. https://doi.org/10.1001/jama.2023.11887.CrossRefPubMedPubMedCentral

13.

Thavendiranathan P, Houbois C, Marwick TH, et al. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother. 2023;9(6):515–25. https://doi.org/10.1093/ehjcvp/pvad031.CrossRefPubMedPubMedCentral

14.

Ludke A, Akolkar G, Ayyappan P, Sharma AK, Singal PK. Time course of changes in oxidative stress and stress-induced proteins in cardiomyocytes exposed to doxorubicin and prevention by vitamin C. PLoS ONE. 2017;12(7): e0179452. https://doi.org/10.1371/journal.pone.0179452.CrossRefPubMedPubMedCentral

15.

Cappetta D, De Angelis A, Sapio L, et al. Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity. Oxid Med Cell Longev. 2017;2017: e1521020. https://doi.org/10.1155/2017/1521020.CrossRef

16.

Songbo M, Lang H, Xinyong C, Bin X, Ping Z, Liang S. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett. 2019;307:41–8. https://doi.org/10.1016/j.toxlet.2019.02.013.CrossRefPubMed

17.

Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–42. https://doi.org/10.1038/nm.2919.CrossRefPubMed

18.

Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971–7. https://doi.org/10.1136/heartjnl-2017-312103.CrossRefPubMed

19.

Bernstein D. Anthracycline Cardiotoxicity. Circ Res. 2018;122(2):188–90. https://doi.org/10.1161/CIRCRESAHA.117.312395.CrossRefPubMedPubMedCentral

20.

Sawicki KT, Sala V, Prever L, Hirsch E, Ardehali H, Ghigo A. Preventing and Treating Anthracycline Cardiotoxicity: New Insights. Annual Review of Pharmacology and Toxicology. 2021;61(Volume 61, 2021):309–332. https://doi.org/10.1146/annurev-pharmtox-030620-104842

21.

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines | European Heart Journal | Oxford Academic. Accessed May 5, 2024. https://academic.oup.com/eurheartj/article/37/36/2768/2197413?login=false

22.

Bhagat A, Kleinerman ES. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. Adv Exp Med Biol. 2020;1257:181–92. https://doi.org/10.1007/978-3-030-43032-0_15.CrossRefPubMed

23.

Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97(11):2869–79. https://doi.org/10.1002/cncr.11407.CrossRefPubMed

24.

Caballero RM, Antolín JMS, Hernández RMJ, et al. Incidence of long-term cardiotoxicity and evolution of the systolic function in patients with breast cancer treated with anthracyclines. Cardiol J. 2022;29(2):228–34. https://doi.org/10.5603/CJ.a2020.0062.CrossRefPubMedCentral

25.

Dranitsaris G, Rayson D, Vincent M, et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat. 2008;107(3):443–50. https://doi.org/10.1007/s10549-007-9803-5.CrossRefPubMed

26.

Mackey JR, Martin M, Pienkowski T, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013;14(1):72–80. https://doi.org/10.1016/S1470-2045(12)70525-9.CrossRefPubMed

27.

Bonneterre J, Roché H, Kerbrat P, et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol. 2004;22(15):3070–9. https://doi.org/10.1200/JCO.2004.03.098.CrossRefPubMed

28.

Narayan HK, French B, Khan AM, et al. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction. JACC Cardiovasc Imaging. 2016;9(10):1131–41. https://doi.org/10.1016/j.jcmg.2015.11.024.CrossRefPubMedPubMedCentral

29.

Serrano JM, Mata R, González I, et al. Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors. Int J Cardiol. 2023;382:52–9. https://doi.org/10.1016/j.ijcard.2023.04.026.CrossRefPubMed

30.

van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;2010(5):CD005006. https://doi.org/10.1002/14651858.CD005006.pub4

31.

Gabizon AA. Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy. Cancer Invest. 2001;19(4):424–36. https://doi.org/10.1081/CNV-100103136.CrossRefPubMed

32.

These highlights do not include all the information needed to use DEXRAZOXANE FOR INJECTION safely and effectively. See full prescribing information for DEXRAZOXANE FOR INJECTION. DEXRAZOXANE for injection, for intravenous use Initial U.S. Approval: 1995. Accessed January 11, 2025. https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/be9ac1e9-21a9-439a-9029-9f03513220ea/spl-doc?hl=dexrazoxane

33.

Macedo AVS, Hajjar LA, Lyon AR, et al. Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer. JACC CardioOncol. 2019;1(1):68–79. https://doi.org/10.1016/j.jaccao.2019.08.003.CrossRefPubMedPubMedCentral

34.

de Baat EC, Mulder RL, Armenian S, et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst Rev. 2022;9(9):CD014638. https://doi.org/10.1002/14651858.CD014638.pub2

35.

Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318–32. https://doi.org/10.1200/JCO.1997.15.4.1318.CrossRefPubMed

36.

Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39(8):974–84. https://doi.org/10.1016/j.ctrv.2013.03.005.CrossRefPubMed

37.

Lanza O, Ferrera A, Reale S, et al. New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies. Med Sci (Basel). 2022;10(2):27. https://doi.org/10.3390/medsci10020027.CrossRefPubMed

38.

Depetris I, Marino D, Bonzano A, et al. Fluoropyrimidine-induced cardiotoxicity. Crit Rev Oncol Hematol. 2018;124:1–10. https://doi.org/10.1016/j.critrevonc.2018.02.002.CrossRefPubMed

39.

Layoun ME, Wickramasinghe CD, Peralta MV, Yang EH. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management. Curr Oncol Rep. 2016;18(6):35. https://doi.org/10.1007/s11912-016-0521-1.CrossRefPubMed

40.

Kanduri J, More LA, Godishala A, Asnani A. Fluoropyrimidine-Associated Cardiotoxicity. Cardiol Clin. 2019;37(4):399–405. https://doi.org/10.1016/j.ccl.2019.07.004.CrossRefPubMed

41.

Cucciniello L, Bidoli E, Viel E, Canale ML, Gerratana L, Lestuzzi C. The puzzling clinical presentation of fluoropyrimidines cardiotoxicity. Front Cardiovasc Med. 2022;9. https://doi.org/10.3389/fcvm.2022.960240

42.

Rajaeinejad M, Parhizkar-Roudsari P, Khoshfetrat M, et al. Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment. Cardiovasc Toxicol. 2024;24(2):184–98. https://doi.org/10.1007/s12012-024-09834-9.CrossRefPubMed

43.

Morelli MB, Bongiovanni C, Da Pra S, et al. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Front Cardiovasc Med. 2022;9: 847012. https://doi.org/10.3389/fcvm.2022.847012.CrossRefPubMedPubMedCentral

44.

Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9(9):1704–12. https://doi.org/10.1200/JCO.1991.9.9.1704.CrossRefPubMed

45.

Tocchetti CG, Cadeddu C, Di Lisi D, et al. From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. Antioxid Redox Signal. 2019;30(18):2110–53. https://doi.org/10.1089/ars.2016.6930.CrossRefPubMedPubMedCentral

46.

Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502. https://doi.org/10.1038/s41569-020-0348-1.CrossRefPubMedPubMedCentral

47.

Shetty N, Gupta S. Eribulin drug review. South Asian J Cancer. 2014;3(1):57–9. https://doi.org/10.4103/2278-330X.126527.CrossRefPubMedPubMedCentral

48.

Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. In: Database of Abstracts of Reviews of Effects (DARE): Quality-Assessed Reviews [Internet]. Centre for Reviews and Dissemination (UK); 2011. Accessed July 19, 2024. https://www.ncbi.nlm.nih.gov/books/NBK82853/

49.

Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Klijin J. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–9.CrossRefPubMed

50.

Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial [published correction appears in Expert Rev Anticancer Ther. 2009 Mar;9(3):388]. Expert Rev Anticancer Ther. 2009;9(1):51–60.

51.

Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52. https://doi.org/10.1016/S0140-6736(04)17018-9.CrossRefPubMed

52.

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–7. https://doi.org/10.1182/blood-2007-10-116327.CrossRefPubMedPubMedCentral

53.

Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology. 2004;63(7):1230–3. https://doi.org/10.1212/01.wnl.0000140491.54664.50.CrossRefPubMed

54.

Biganzoli L, Cinieri S, Berardi R, et al. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. Breast Cancer Res. 2020;22(1):83. https://doi.org/10.1186/s13058-020-01319-1.CrossRefPubMedPubMedCentral

55.

Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022;40(28):3246–56. https://doi.org/10.1200/JCO.22.00338.CrossRefPubMedPubMedCentral

56.

Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91. https://doi.org/10.1056/NEJMoa1103507.CrossRefPubMed

57.

Cuzick J, Sestak I, Forbes JF, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet. 2020;395(10218):117–22. https://doi.org/10.1016/S0140-6736(19)32955-1.CrossRefPubMedPubMedCentral

58.

Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol. 2007;25(5):486–92. https://doi.org/10.1200/JCO.2006.08.8617.CrossRefPubMed

59.

Foglietta J, Inno A, de Iuliis F, et al. Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. Clin Breast Cancer. 2017;17(1):11–7. https://doi.org/10.1016/j.clbc.2016.07.003.CrossRefPubMed

60.

Yoo JJ, Jung EA, Kim Z, Kim BY. Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis. Curr Oncol. 2023;30(2):1831–43. https://doi.org/10.3390/curroncol30020142.CrossRefPubMedPubMedCentral

61.

Lin E, Garmo H, Van Hemelrijck M, et al. Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes. JAMA Netw Open. 2022;5(8): e2225600. https://doi.org/10.1001/jamanetworkopen.2022.25600.CrossRefPubMedPubMedCentral

62.

Pagani O, Walley BA, Fleming GF, et al. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023;41(7):1376–82. https://doi.org/10.1200/JCO.22.01064.CrossRefPubMed

63.

Chou YS, Wang CC, Hsu LF, et al. Gonadotropin-releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: A cohort study. Cancer Med. 2023;12(5):5536–44. https://doi.org/10.1002/cam4.5390.CrossRefPubMed

64.

Lim MWS, Lucas-Herald AK, Mason A, Delles C, Connelly PJ. Sex differences in the cardiovascular effects of GnRH analogues. J Endocrinol. 2024;261(1): e230309. https://doi.org/10.1530/JOE-23-0309.CrossRefPubMed

65.

Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77–90. https://doi.org/10.1016/S1470-2045(22)00694-5.CrossRefPubMed

66.

Dennis S, Oleg L, Zbigniew N, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024;390(12):1080–91. https://doi.org/10.1056/NEJMoa2305488.CrossRef

67.

West MT, Smith CE, Kaempf A, et al. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. Eur J Haematol. 2021;106(5):634–42. https://doi.org/10.1111/ejh.13590.CrossRefPubMedPubMedCentral

68.

Thein KZ, Htut TW, Ball S, Swarup S, Sultan A, Oo TH. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2020;183(2):479–87. https://doi.org/10.1007/s10549-020-05783-3.CrossRefPubMed

69.

Rugo HS, O’Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33(6):616–27. https://doi.org/10.1016/j.annonc.2022.03.006.CrossRefPubMed

70.

Fiste O, Liontos M, Gavriatopoulou M, et al. CDK4/6 inhibitors and cardiovascular toxicity: Real-world evidence. JCO. 2023;41(16_suppl):e15074-e15074. https://doi.org/10.1200/JCO.2023.41.16_suppl.e15074

71.

Burris HA, Chan A, Bardia A, et al. Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. Br J Cancer. 2021;125(5):679–86. https://doi.org/10.1038/s41416-021-01415-9.CrossRefPubMedPubMedCentral

72.

Im Seock-Ah Lu, Yen-Shen BA, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381(4):307–16. https://doi.org/10.1056/NEJMoa1903765.CrossRefPubMed

73.

Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Pharmacol Ther. 2018;189:89–103. https://doi.org/10.1016/j.pharmthera.2018.04.009.CrossRefPubMed

74.

Lyon A. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). https://doi.org/10.1093/eurheartj/ehac244

75.

Finn RS, Rugo HS, Gelmon KA, et al. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. Oncologist. 2021;26(5):e749–55. https://doi.org/10.1002/onco.13684.CrossRefPubMedPubMedCentral

76.

Rugo HS, Huober J, García-Sáenz JA, et al. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021;26(1):e53–65. https://doi.org/10.1002/onco.13531.CrossRefPubMed

77.

Slamon DJ, Leyland-Jones B, Shak S, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med. 2001;344(11):783–92. https://doi.org/10.1056/NEJM200103153441101.CrossRefPubMed

78.

Dennis S, Wolfgang E, Nicholas R, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med. 2011;365(14):1273–83. https://doi.org/10.1056/NEJMoa0910383.CrossRef

79.

Ganz PA, Romond EH, Cecchini RS, et al. Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. JCO. 2017;35(35):3942–8. https://doi.org/10.1200/JCO.2017.74.1165.CrossRef

80.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med. 2005;353(16):1659–72. https://doi.org/10.1056/NEJMoa052306.CrossRefPubMed

81.

Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. 2017;389(10075):1195–205. https://doi.org/10.1016/S0140-6736(16)32616-2.CrossRef

82.

Conte P, Bisagni G, Piacentini F, et al. Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial. JCO. 2023;41(32):4976–81. https://doi.org/10.1200/JCO.23.00790.CrossRef

83.

Mavroudis D, Saloustros E, Malamos N, et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2015;26(7):1333–40. https://doi.org/10.1093/annonc/mdv213.CrossRefPubMed

84.

Conte P, Frassoldati A, Bisagni G, et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Ann Oncol. 2018;29(12):2328–33. https://doi.org/10.1093/annonc/mdy414.CrossRefPubMed

85.

Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555):29–36. https://doi.org/10.1016/S0140-6736(07)60028-2.CrossRefPubMed

86.

Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32. https://doi.org/10.1016/S1470-2045(11)70336-9.CrossRefPubMed

87.

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | New England Journal of Medicine. Accessed May 22, 2024. https://www-nejm-org.ezproxy.uvm.edu/doi/full/https://doi.org/10.1056/NEJMoa1413513

88.

von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122–31. https://doi.org/10.1056/NEJMoa1703643.CrossRef

89.

Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;29(3):646–53. https://doi.org/10.1093/annonc/mdx773.CrossRefPubMed

90.

Rugo HS, Im SA, Cardoso F, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(4):573–84. https://doi.org/10.1001/jamaoncol.2020.7932.CrossRefPubMed

91.

Sunil V, David M, Luca G, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012;367(19):1783–91. https://doi.org/10.1056/NEJMoa1209124.CrossRef

92.

Perez EA, Barrios C, Eiermann W, et al. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. JCO. 2017;35(2):141–8. https://doi.org/10.1200/JCO.2016.67.4887.CrossRef

93.

von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617–28. https://doi.org/10.1056/NEJMoa1814017.CrossRef

94.

Krop IE, Im SA, Barrios C, et al. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study. JCO. 2022;40(5):438–48. https://doi.org/10.1200/JCO.21.00896.CrossRef

95.

Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. The Lancet. 2023;401(10371):105–17. https://doi.org/10.1016/S0140-6736(22)02420-5.CrossRef

96.

Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020;31(12):1709–18. https://doi.org/10.1016/j.annonc.2020.09.004.CrossRefPubMed

97.

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01. Journal of Clinical Oncology. Accessed April 24, 2024. https://ascopubs.org/doi/https://doi.org/10.1200/JCO.23.00059

98.

Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). Journal of Clinical Oncology. Accessed April 24, 2024. https://ascopubs.org/doi/https://doi.org/10.1200/JCO.2022.40.16_suppl.1002

99.

Geyer CE, Chan S, Jagiello-Gruszfeld A, Kaufman B, Davidson N, Rubin SD. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. The New England Journal of Medicine. Published online 2006.

100.

Choi HD, Chang MJ. Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis. Breast Cancer Res Treat. 2017;166(3):927–36. https://doi.org/10.1007/s10549-017-4460-9.CrossRefPubMed

101.

Murthy Rashmi K., Loi Sherene, Okines Alicia, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine. 2020;382(7):597–609. https://doi.org/10.1056/NEJMoa1914609

102.

Im YH, Karabulut B, Lee KS, et al. Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES. Breast Cancer Res Treat. 2021;188(1):77–89. https://doi.org/10.1007/s10549-021-06173-z.CrossRefPubMed

103.

Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9. https://doi.org/10.1056/NEJMoa1109653.CrossRefPubMed

104.

Royce M, Bachelot T, Villanueva C, et al. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial. JAMA Oncol. 2018;4(7):977–84. https://doi.org/10.1001/jamaoncol.2018.0060.CrossRefPubMedPubMedCentral

105.

Turner Nicholas C., Oliveira Mafalda, Howell Sacha J., et al. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine. 2023;388(22):2058–2070. https://doi.org/10.1056/NEJMoa2214131

106.

Fabrice A, Eva C, Gabor R, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929–40. https://doi.org/10.1056/NEJMoa1813904.CrossRef

107.

Peter S, Javier C, Lajos P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810–21. https://doi.org/10.1056/NEJMoa1910549.CrossRef

108.

Cortes Javier, Rugo Hope S., Cescon David W., et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 2022;387(3):217–226. https://doi.org/10.1056/NEJMoa2202809

109.

Naqash AR, Moey MYY, Cherie Tan XW, et al. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program. J Clin Oncol. 2022;40(29):3439–52. https://doi.org/10.1200/JCO.22.00369.CrossRefPubMedPubMedCentral

110.

Dolladille C, Akroun J, Morice PM, et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021;42(48):4964–77. https://doi.org/10.1093/eurheartj/ehab618.CrossRefPubMed

111.

Makunts T, Saunders IM, Cohen IV, et al. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep. 2021;11:17324. https://doi.org/10.1038/s41598-021-96467-5.CrossRefPubMedPubMedCentral

112.

Salem JE, Manouchehri A, Moey M, et al. Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: A pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–89. https://doi.org/10.1016/S1470-2045(18)30608-9.CrossRefPubMedPubMedCentral

113.

He Y, Yu H, Dai S, et al. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology Genes Dis. 2023;11(2):807–18. https://doi.org/10.1016/j.gendis.2023.01.024.CrossRefPubMed

114.

Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64. https://doi.org/10.1016/j.jacc.2018.02.037.CrossRefPubMedPubMedCentral

115.

Drobni ZD, Alvi RM, Taron J, et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020;142(24):2299–311. https://doi.org/10.1161/CIRCULATIONAHA.120.049981.CrossRefPubMedPubMedCentral

116.

Li X, Peng W, Wu J, Yeung SCJ, Yang R. Advances in immune checkpoint inhibitors induced-cardiotoxicity. Front Immunol. 2023;14. https://doi.org/10.3389/fimmu.2023.1130438

117.

Guidelines Detail. NCCN. Accessed June 18, 2024. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419

118.

Schneider B. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. 2021–11–01. 39. https://doi.org/10.1200/JCO.21.01440

119.

Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911. https://doi.org/10.1200/JCO.2016.70.5400.CrossRefPubMed

Title: Cardio-Oncology and Breast Cancer Therapies
Authors: Rohit Singh
Krina Patel
Haze Xu
Aderonke Adeniyi
Jenica N. Upshaw
Peter Van Buren
Peter A. Kaufman
Kim Dittus
Kara K. Landry
Publication date: 21-04-2025
Publisher: Springer US
Keywords: Anthracycline
Breast Cancer
Breast Cancer
Heart Failure
Tamoxifen
Trastuzumab
Published in: Current Treatment Options in Oncology / Issue 5/2025
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-025-01311-x

Managing bone metastases in gynecologic malignancies

Gynecologic Cancer
Review

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook

Open Access
Pleural Mesothelioma
REVIEW

Emerging Advances in the Molecular Landscape of Penile Cancer and Their Implications for Precision Medicine

Human Papillomavirus
REVIEW

Role of Geriatric Assessment in Hematopoietic Stem Cell Transplant and Cellular Therapies

Geriatric Assessment
REVIEW

Therapeutic Challenges in the Management of Serous Endometrial Intraepithelial Carcinoma (SEIC)

Endometrial Cancer
REVIEW

Oral Budesonide in Oncology: A Novel Approach to Managing Gastrointestinal Immune-Related Adverse Events

Budesonide

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Genetic Testing
On-demand Webinar

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:

Illumina, Inc., and Eli Lilly and Company

Dr. Vivek Subbiah

Dr. Alexander Drilon

Dr. Michelle Williams

Developed by: Springer Healthcare

Watch now

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Cardio-Oncology and Breast Cancer Therapies

Opinion Statement

Other articles of this Issue 5/2025

Managing bone metastases in gynecologic malignancies

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook

Emerging Advances in the Molecular Landscape of Penile Cancer and Their Implications for Precision Medicine

Role of Geriatric Assessment in Hematopoietic Stem Cell Transplant and Cellular Therapies

Therapeutic Challenges in the Management of Serous Endometrial Intraepithelial Carcinoma (SEIC)

Oral Budesonide in Oncology: A Novel Approach to Managing Gastrointestinal Immune-Related Adverse Events

Women’s health knowledge hub

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

Elevate your expertise in aplastic anemia (Link opens in a new window)

Springer Medicine

Opinion Statement

Please log in to get access to this content